The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study
- PMID: 3539613
- DOI: 10.1093/oxfordjournals.eurheartj.a061969
The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study
Abstract
Twenty-four patients with stable exercise-induced angina pectoris entered a double-blind cross-over study. Isosorbide-5-mononitrate (5-ISMN) 60 mg in a controlled release formulation (Durules) given once daily was compared with identical placebo. The exercise tolerance was determined by bicycle ergometry before and 3 h after a single dose of 5-ISMN and following one week's treatment with 5-ISMN and placebo. Nineteen patients completed the study. Exercise tolerance until the onset of chest pain and until 1 mm ST segment depression increased significantly 3 h after dose. The same increase was seen both after a single dose and the same dose under steady-state conditions. No increase was seen with placebo. The heart rate and systolic blood pressure reactions in the standing position were less pronounced 3 h after dose in steady-state than after a single dose of 5-ISMN. Headache was the only bothersome side-effect reported. The study demonstrates that 60 mg 5-ISMN in a Durules formulation given once daily has a significant anti-anginal effect and that tolerance does not develop.
Similar articles
-
Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to beta-blocking agents in patients with stable angina pectoris.J Cardiovasc Pharmacol. 1989 Sep;14(3):358-63. doi: 10.1097/00005344-198909000-00002. J Cardiovasc Pharmacol. 1989. PMID: 2476613 Clinical Trial.
-
Anti-anginal efficacy of a controlled-release formulation of isosorbide-5-mononitrate once daily in angina patients on chronic beta-blockade.Acta Med Scand. 1988;223(3):219-25. doi: 10.1111/j.0954-6820.1988.tb15790.x. Acta Med Scand. 1988. PMID: 2895564 Clinical Trial.
-
Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.Eur Heart J. 1994 Jan;15(1):108-13. doi: 10.1093/oxfordjournals.eurheartj.a060361. Eur Heart J. 1994. PMID: 8174569 Clinical Trial.
-
Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.Drugs. 1999 Feb;57(2):261-77. doi: 10.2165/00003495-199957020-00016. Drugs. 1999. PMID: 10188765 Review.
-
Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.Angiology. 2000 Aug;51(8):631-8. Angiology. 2000. PMID: 10959515 Review.
Cited by
-
Clinical experience with Imdur in angina pectoris. A review.Eur J Clin Pharmacol. 1990;38 Suppl 1:S65-8. doi: 10.1007/BF01417567. Eur J Clin Pharmacol. 1990. PMID: 1972359 Review.
-
Short and long-acting oral nitrates for stable angina pectoris.Cardiovasc Drugs Ther. 1994 Aug;8(4):611-23. doi: 10.1007/BF00877415. Cardiovasc Drugs Ther. 1994. PMID: 7848896 Review.
-
Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil.Eur J Clin Pharmacol. 1990;38 Suppl 1:S31-4. doi: 10.1007/BF01417563. Eur J Clin Pharmacol. 1990. PMID: 2354712
-
Prophylactic nitrate therapy in angina pectoris--is there an optimal treatment regimen?Br J Clin Pharmacol. 1992;34 Suppl 1(Suppl 1):19S-23S. doi: 10.1111/j.1365-2125.1992.tb04144.x. Br J Clin Pharmacol. 1992. PMID: 1633074 Free PMC article. Review.
-
An update on nitrate tolerance: can it be avoided?Postgrad Med J. 1992 Nov;68(805):857-66. doi: 10.1136/pgmj.68.805.857. Postgrad Med J. 1992. PMID: 1494507 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical